Polycomb repressive complex 2 in the driver's seat of childhood and young adult brain tumours

Trends Cell Biol. 2021 Oct;31(10):814-828. doi: 10.1016/j.tcb.2021.05.006. Epub 2021 Jun 3.

Abstract

Deregulation of the epigenome underlies oncogenesis in numerous primary brain tumours in children and young adults. In this review, we describe how recurrent mutations in isocitrate dehydrogenases or histone 3 variants (oncohistones) in gliomas, expression of the oncohistone mimic enhancer of Zeste homologs inhibiting protein (EZHIP) in a subgroup of ependymoma, and epigenetic alterations in other embryonal tumours promote oncogenicity. We review the proposed mechanisms of cellular transformation, current tumorigenesis models and their link to development. We further stress the narrow developmental windows permissive to their oncogenic potential and how this may stem from converging effects deregulating polycomb repressive complex (PRC)2 function and targets. As altered chromatin states may be reversible, improved understanding of aberrant cancer epigenomes could orient the design of effective therapies.

Keywords: EZH inhibiting protein; epigenome; glioma; isocitrate dehydrogenases; polycomb repressive complex 2.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Brain Neoplasms* / genetics
  • Child
  • Ependymoma* / genetics
  • Glioma* / genetics
  • Humans
  • Oncogenes
  • Polycomb Repressive Complex 1
  • Polycomb Repressive Complex 2 / genetics

Substances

  • Polycomb Repressive Complex 2
  • Polycomb Repressive Complex 1